Linking drug target and pathway activation for effective therapy using multi-task learning

Despite the abundance of large-scale molecular and drug-response data, the insights gained about the mechanisms underlying treatment efficacy in cancer has been in general limited. Machine learning algorithms applied to those datasets most often are used to provide predictions without interpretation, or reveal single drug-gene association and fail to derive robust insights. We propose to use Macau, a bayesian multitask multi-relational algorithm to generalize from individual drugs and genes and explore the interactions between the drug targets and signaling pathways’ activation. A typical insight would be: “Activation of pathway Y will confer sensitivity to any drug targeting protein X”. We applied our methodology to the Genomics of Drug Sensitivity in Cancer (GDSC) screening, using gene expression of 990 cancer cell lines, activity scores of 11 signaling pathways derived from the tool PROGENy as cell line input and 228 nominal targets for 265 drugs as drug input. These interactions can guide a tissue-specific combination treatment strategy, for example suggesting to modulate a certain pathway to maximize the drug response for a given tissue. We confirmed in literature drug combination strategies derived from our result for brain, skin and stomach tissues. Such an analysis of interactions across tissues might help target discovery, drug repurposing and patient stratification strategies.

[1]  Kazuyuki Kojima,et al.  Clinical significance of MET in gastric cancer. , 2015, World journal of gastrointestinal oncology.

[2]  Emanuel J. V. Gonçalves,et al.  A Landscape of Pharmacogenomic Interactions in Cancer , 2016, Cell.

[3]  J. Tait,et al.  Challenges and opportunities. , 1996, Journal of psychiatric and mental health nursing.

[4]  Davide Corà,et al.  VEGF blockade enhances the antitumor effect of BRAFV 600E inhibition , 2016, EMBO molecular medicine.

[5]  M. Karin,et al.  Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. , 1995, Science.

[6]  Nasser Ghadiri,et al.  A review of network‐based approaches to drug repositioning , 2018, Briefings Bioinform..

[7]  Joshua A. Bittker,et al.  Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset. , 2015, Cancer discovery.

[8]  J. Ruland,et al.  Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. , 2007, Blood.

[9]  Jian Jin,et al.  Topoisomerase 1 inhibition suppresses inflammatory genes and protects from death by inflammation , 2016, Science.

[10]  P. Lorigan,et al.  TNF-α increases human melanoma cell invasion and migration in vitro: the role of proteolytic enzymes , 2003, British Journal of Cancer.

[11]  Sung Kim,et al.  HER2‐positive gastric cancer with concomitant MET and/or EGFR overexpression: A distinct subset of patients for dual inhibition therapy , 2015, International journal of cancer.

[12]  Bob van de Water,et al.  MEK inhibition induces apoptosis in osteosarcoma cells with constitutive ERK1/2 phosphorylation , 2015, Genes & cancer.

[13]  Julio Saez-Rodriguez,et al.  Machine Learning Prediction of Cancer Cell Sensitivity to Drugs Based on Genomic and Chemical Properties , 2012, PloS one.

[14]  Nci Dream Community A community effort to assess and improve drug sensitivity prediction algorithms , 2014 .

[15]  Wei Gu,et al.  Dual Roles of MDM2 in the Regulation of p53: Ubiquitination Dependent and Ubiquitination Independent Mechanisms of MDM2 Repression of p53 Activity. , 2012, Genes & cancer.

[16]  Krister Wennerberg,et al.  Integrative and Personalized QSAR Analysis in Cancer by Kernelized Bayesian Matrix Factorization , 2014, J. Chem. Inf. Model..

[17]  J. Trédaniel,et al.  Neurotensin and its high affinity receptor 1 as a potential pharmacological target in cancer therapy , 2013, Front. Endocrin..

[18]  Hristo S. Paskov,et al.  Multitask learning improves prediction of cancer drug sensitivity , 2016, Scientific Reports.

[19]  Krister Wennerberg,et al.  Systematic identification of feature combinations for predicting drug response with Bayesian multi-view multi-task linear regression , 2017, Bioinform..

[20]  Mehmet Gönen,et al.  Drug susceptibility prediction against a panel of drugs using kernelized Bayesian multitask learning , 2014, Bioinform..

[21]  Yves Moreau,et al.  Macau: Scalable Bayesian factorization with high-dimensional side information using MCMC , 2017, 2017 IEEE 27th International Workshop on Machine Learning for Signal Processing (MLSP).

[22]  Joseph A. DiDonato,et al.  Immunosuppression by Glucocorticoids: Inhibition of NF-κB Activity Through Induction of IκB Synthesis , 1995, Science.

[23]  Edwin Wang,et al.  Signaling network assessment of mutations and copy number variations predict breast cancer subtype-specific drug targets. , 2013, Cell reports.

[24]  Adam A. Margolin,et al.  Addendum: The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity , 2012, Nature.

[25]  Adam A. Margolin,et al.  The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.

[26]  George Papadatos,et al.  Beyond the hype: deep neural networks outperform established methods using a ChEMBL bioactivity benchmark set , 2017, bioRxiv.

[27]  David Meyre,et al.  From big data analysis to personalized medicine for all: challenges and opportunities , 2015, BMC Medical Genomics.

[28]  David Rogers,et al.  Extended-Connectivity Fingerprints , 2010, J. Chem. Inf. Model..

[29]  J. Sáez-Rodríguez,et al.  Perturbation-response genes reveal signaling footprints in cancer gene expression , 2016, Nature Communications.

[30]  G. Robertson,et al.  Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail. , 2010, Biochemical pharmacology.

[31]  Mehmet Gönen,et al.  Modeling gene‐wise dependencies improves the identification of drug response biomarkers in cancer studies , 2017, Bioinform..

[32]  Webster K. Cavenee,et al.  Orthogonal targeting of EGFRvIII expressing glioblastomas through simultaneous EGFR and PLK1 inhibition , 2015, Oncotarget.

[33]  Qiang Yang,et al.  A Survey on Transfer Learning , 2010, IEEE Transactions on Knowledge and Data Engineering.

[34]  Ivan Babic,et al.  Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance. , 2011, Cancer discovery.

[35]  S Marsoni,et al.  Dual MET/EGFR therapy leads to complete response and resistance prevention in a MET-amplified gastroesophageal xenopatient cohort , 2017, Oncogene.

[36]  Isidro Cortes-Ciriano,et al.  Current Trends in Drug Sensitivity Prediction. , 2017, Current pharmaceutical design.